Trial Profile
VP-VLY-686-1301: A Single Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Tradipitant (Primary)
- Indications Atopic dermatitis; COVID 2019 infections; Gastroparesis; Motion sickness; Pruritus
- Focus Pharmacodynamics
- Sponsors Vanda Pharmaceuticals
- 19 Mar 2024 Status changed from recruiting to completed.
- 29 May 2022 Primary endpoint (Gastric emptying half-time of solids as measured by scintigraphy) has not been met according to the results published in the Alimentary Pharmacology and Therapeutics
- 29 May 2022 Primary endpoint (Satiation expressed as volume to fullness as measured by satiation test) has not been met according to the results published in the Alimentary Pharmacology and Therapeutics